Citations Report

Clinical Investigation : Citations & Metrics Report

Articles published in Clinical Investigation have been cited by esteemed scholars and scientists all around the world.

Clinical Investigation has got h-index 28, which means every article in Clinical Investigation has got 28 average citations.

Following are the list of articles that have cited the articles published in Clinical Investigation.

• Gridelli, Cesare, et al. "ALK inhibitors in the treatment of advanced NSCLC." Cancer treatment reviews 40.2 (2014): 300-306. View at Publisher | View at Google Scholar | View at Indexing
• Camidge, D. Ross, and Robert C. Doebele. "Treating ALK-positive lung cancer—early successes and future challenges." Nature reviews Clinical oncology 9.5 (2012): 268-277. View at Publisher | View at Google Scholar | View at Indexing
• Ettinger, David S., et al. "Non–small cell lung cancer, version 6.2015." Journal of the National Comprehensive Cancer Network 13.5 (2015): 515-524. View at Publisher | View at Google Scholar | View at Indexing
• Leuchs AK, Zinserling J, Brandt A, Wirtz D, Benda N (2015) Choosing appropriate estimands in clinical trials. Therapeutic Innovation & Regulatory Science 49:584-92. View at Publisher | View at Google Scholar | View at Indexing
• Davies, Kurtis D., et al. "Identifying and targeting ROS1 gene fusions in non–small cell lung cancer." Clinical Cancer Research 18.17 (2012): 4570-4579. View at Publisher | View at Google Scholar | View at Indexing
• Camidge, D. Ross, et al. "Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study." The lancet oncology 13.10 (2012): 1011-1019. View at Publisher | View at Google Scholar | View at Indexing
• Permutt T. A taxonomy of estimands for regulatory clinical trials with discontinuations. Statistics in medicine 35: 2865–2875. View at Publisher | View at Google Scholar | View at Indexing
• Permutt T (2015) Sensitivity analysis for missing data in regulatory submissions. Statistics in medicine 35: 2876–2879. View at Publisher | View at Google Scholar | View at Indexing
• Leuchs AK, Brandt A, Zinserling J, Benda N (2016) Disentangling estimands and the intentionâ€Âtoâ€Âtreat principle. Pharmaceutical Statistics 16: 12-19. View at Publisher | View at Google Scholar | View at Indexing

• Kenward MG (2015) Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation. Clinical Investigation. 5: 311-20.

  View at Publisher | View at Google Scholar

• Shih WJ (2016) Comments on the three papers by the FDA/CDER research team on the regulatory perspective of the missing data problem. Statistics in Medicine 35: 2880-6.

  View at Publisher | View at Google Scholar
• Permutt T, Li F (2016) Trimmed means for symptom trials with dropouts. Pharmaceutical Statistics. 16: 20-28. View at Publisher | View at Google Scholar | View at Indexing
• Lehrer E, Mullol J, Agredo F, Alobid I (2014) Management of chronic rhinosinusitis in asthma patients: is there still a debate?. Current allergy and asthma reports 14:1-6. View at Publisher | View at Google Scholar | View at Indexing

• Hall KT, Loscalzo J, Kaptchuk TJ (2015) Genetics and the placebo effect: the placebome. Trends in molecular medicine 21: 285-94.

  View at Publisher | View at Google Scholar

• Colloca L, Grillon C (2014) Understanding placebo and nocebo responses for pain management. Current pain and headache reports 18: 1-7.

  View at Publisher | View at Google Scholar

• Wendt L, Albring A, Benson S, Engler H, Engler A, et al. (2014) Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses. PLoS One 9:e107665.

  View at Publisher | View at Google Scholar

• Benedetti F, Frisaldi E (2014) Creating placebo responders and nonresponders in the laboratory: boons and banes. Pain 4:165-7.

  View at Publisher | View at Google Scholar

• Medoff ZM, Colloca L (2015) Placebo analgesia: understanding the mechanisms. Pain management 5: 89-96.

  View at Publisher | View at Google Scholar

• MacPherson H, Hammerschlag R, Coeytaux RR, Davis RT, Harris RE, et al. (2016) Unanticipated insights into biomedicine from the study of acupuncture. The Journal of Alternative and Complementary Medicine 22: 101-7.

  View at Publisher | View at Google Scholar

• Le Prell CG, Lobarinas E (2016) Clinical and translational research: challenges to the field. InTranslational Research in Audiology, Neurotology, and the Hearing Sciences 58: 241-265.

  View at Publisher | View at Google Scholar
• Rutkowski, Piotr, et al. "Characterization and Clinical Utility of BRAFV600 Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma." Cancers 13.14 (2021): 3591. View at Publisher | View at Google Scholar | View at Indexing
• McAleer, Mary Frances, et al. "Management of melanoma brain metastases." Melanoma management 2.3 (2015): 225-239. View at Publisher | View at Google Scholar | View at Indexing

• McDonnell T (2014) Take Two Sugar Pills and Call Me in the Morning Genetic tests can predict when placebos may be the best medicine.

  View at Publisher | View at Google Scholar
• Trinh, Van Anh, Yan You, and Wen-Jen Hwu. "Treatment of BRAF-mutated advanced cutaneous melanoma." Chinese clinical oncology 3.3 (2014): 28-28. View at Publisher | View at Google Scholar | View at Indexing

• Bloch ED (2014) Take Two Sugar Pills and Call Me in the Morning Genetic tests can predict when placebos may be the best medicine.

  View at Publisher | View at Google Scholar
• Trinh, Van Anh, et al. "Dabrafenib therapy for advanced melanoma." Annals of Pharmacotherapy 48.4 (2014): 519-529. View at Publisher | View at Google Scholar | View at Indexing

• Hartogsohn I (2016) Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology 30: 1259-67.

  View at Publisher | View at Google Scholar

• Cepelewicz J (2014)Take Two Sugar Pills and Call Me in the Morning Genetic tests can predict when placebos may be the best medicine.

  View at Publisher | View at Google Scholar
• Mattei, P. L., et al. "Cutaneous effects of BRAF inhibitor therapy: a case series." Annals of oncology 24.2 (2013): 530-537. View at Publisher | View at Google Scholar | View at Indexing
• Campbell J, King NB (2016) “Unsettling circularity”: Clinical trial enrichment and the evidentiary politics of chronic pain. BioSocieties: 1-26. View at Publisher | View at Google Scholar | View at Indexing
• Nepali K, Ojha R, Lee HY, Liou JP (2016) Early investigational tubulin inhibitors as novel cancer therapeutics. Expert opinion on investigational drugs 25:917-36. View at Publisher | View at Google Scholar | View at Indexing
• Rayner, Brian L. "The importance of guidelines: comment." Cardiovascular Journal of Africa 25.6 (2014): 296-297. View at Publisher | View at Google Scholar | View at Indexing
• K Khurana R, Mahajan M, Kapoor S, Jain S, Singh B (2016) The Sojourn from Parenteral to Oral Taxanes using Nanocarrier Systems: A Patent Review. Recent patents on drug delivery & formulation 10:44-58. View at Publisher | View at Google Scholar | View at Indexing
• Rayner, Brian L. "Erika SW Jones, MB BCh, FCP, Cert Nephrol, PhD, eswjones@ gmail. com." CARDIOVASCULAR JOURNAL OF AFRICA 25.6 (2014). View at Publisher | View at Google Scholar | View at Indexing
• Jang Y, Chung HJ, Hong JW, Yun CW, Chung H (2017) Absorption mechanism of DHP107, an oral paclitaxel formulation that forms a hydrated lipidic sponge phase. Acta Pharmacologica Sinica 38:133-45. View at Publisher | View at Google Scholar | View at Indexing
• Minesh, Patel, and G. S. Chakraborthy. "A role of clinical trial in management of hypertension and medication of hypertension." Research Journal of Pharmacy and Technology 14.6 (2021): 3215-3222. View at Publisher | View at Google Scholar | View at Indexing
• Wei, Yu-meng, et al. "Formulation and pharmacokinetic evaluation of once-daily sustained-released system of nifedipine with solid dispersion and coating techniques." Archives of pharmacal research 36.7 (2013): 864-873. View at Publisher | View at Google Scholar | View at Indexing
• Baldelli S, Cattaneo D, Pignatelli P, Perrone V, Pastori D, et al. (2016) Validation of an LC–MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. Bioanalysis 8:275-83. View at Publisher | View at Google Scholar | View at Indexing
• Meier P. renal artery stenosis (2011) Medical therapy for atherosclerotic renal artery stenosis Clin. Invest. 1075–1077. View at Publisher | View at Google Scholar | View at Indexing
• Burgess JT, Croft LV, Wallace NC, Stephenson SA, Adams MN, et al. (2014) DNA repair pathways and their therapeutic potential in lung cancer. Lung Cancer 3:159-73. View at Publisher | View at Google Scholar | View at Indexing

• Fox CB, Haensler J (2013) An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert review of vaccines 12:747-58.

  View at Publisher | View at Google Scholar
• A Day T, G Kublin J (2013) Lessons learned from HIV vaccine clinical efficacy trials. Current HIV research 11: 441-9. View at Publisher | View at Google Scholar | View at Indexing
• Day T, Morgan C (2013) Probing scientific questions to advance HIV vaccine development. View at Publisher | View at Google Scholar | View at Indexing
• Mercuri E, Muntoni F(2013) Muscular dystrophies. The Lancet ;381:8458-60. View at Publisher | View at Google Scholar | View at Indexing
• Eleftheriadou V (2013) Future horizons in vitiligo research: focusing on the recommendations of the Cochrane systematic review ‘Interventions for vitiligo’2010. British Journal of Dermatology 169: 67-70. View at Publisher | View at Google Scholar | View at Indexing
• McGreevy JW, Hakim CH, McIntosh MA, Duan D.(2015) Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Disease models & mechanisms. ;8:195-213. View at Publisher | View at Google Scholar | View at Indexing
• Oka Y, Tsuboi A, Nakajima H, Fujiki F, Nishida S, et al. (2016) WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives. InImmunotherapy of Cancer: 159-185. View at Publisher | View at Google Scholar | View at Indexing
• Hennekens CH, Dalen JE (2014)Aspirin in the primary prevention of cardiovascular disease: Current knowledge and future research needs. Trends in cardiovascular medicine 24: 360-6. View at Publisher | View at Google Scholar | View at Indexing
• Hennekens CH, Bjorkman DJ (2014) Evolving concepts in the primary prevention of cardiovascular disease: aspirin then and now. Future cardiology 10: 583-6. View at Publisher | View at Google Scholar | View at Indexing
• Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S.,et.al.. (2013) 24 month longitudinal data in ambulant boys with duchenne muscular dystrophy. PloS one ;8:e52512. View at Publisher | View at Google Scholar | View at Indexing